Molika Ashford
Molika Ashford covers personalized medicine and molecular diagnostics for GenomeWeb.

Articles Authored by Molika Ashford
The company analyzed MRD status in samples from a prior failed study, showing a significant benefit from the drug for ctDNA-positive patients.
The retrospective results suggest that the test's sensitivity boost over other platforms can overcome the challenge of detecting ctDNA in adenocarcinomas.
The NCI-led Vanguard study has selected tests from Guardant Health and ClearNote Health to move forward after a vigorous technology assessment.

Data from Myriad Genetics offered early validation evidence for an expanded version of its commercial test, as well as a look into clinical impact via claims data.
The McGill University team is advancing a test, dubbed DOvEEgene, which sequences DNA from a uterine brush sample to detect cancer-associated mutations.
Pathologists See Value Balance Shift Toward Comprehensive Sequencing for Hematologic Cancers
Premium
At the AMP annual meeting last week, speakers at multiple workshops said their field is reaching a tipping point as the clinical utility of NGS further solidifies.
The research hospital is working to further validate and refine its approach, aiming to arm clinicians with a more comprehensive tool to personalize care.

As the company explores new testing areas and technologies, the prostate cancer prognostic has become an important backbone.
Exact Sciences Stock Tumbles After Firm Lowers Full-Year Revenue Guidance, Misses Q3 Estimates
The company's CEO said that results and resulting downward adjustment of its full-year guidance don't reflect its true potential, citing plans to do better in 2025.
A recent survey by GenomeWeb revealed trends in the adoption and usage of various types of circulating tumor DNA assays for solid tumors.
